EZH2 and lymphoma: Mechanistically, treatment with compound 15 reduced the cellular H3K27me3 levels and caused a broad range of transcriptional activation of EZH2/PRC2 target genes in sensitive lymphoma cells, while it did not significantly affect the gene expression patterns of insensitive cells.